Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Cross-reactivity00:42

Cross-reactivity

Overview
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergence and antigenic characterisation of influenza A(H3N2) viruses with hemagglutinin substitutions N158K and K189R during the 2024/25 influenza season.

bioRxiv : the preprint server for biology·2026
Same author

Highly Pathogenic Avian Influenza Virus A/H5N1 Subclade 2.3.4.4b Isolated from a European Grey Seal (Halichoerus grypus) Is Highly Virulent in Ferrets.

The Journal of infectious diseases·2025
Same author

Swine influenza virus surveillance programme pilot to assess the risk for animal and public health, the Netherlands, 2022 to 2023.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2025
Same author

Intravenous SARS-CoV-2 Spike protein induces neuroinflammation and alpha-Synuclein accumulation in brain regions relevant to Parkinson's disease.

Brain, behavior, and immunity·2025
Same author

Human infections with Eurasian avian-like swine influenza virus detected by coincidence via routine respiratory surveillance systems, the Netherlands, 2020 to 2023.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2025
Same author

Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies - A stakeholder meeting report.

Biologicals : journal of the International Association of Biological Standardization·2025

Related Experiment Video

Updated: May 29, 2026

Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays
13:12

Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays

Published on: April 4, 2011

Towards universal influenza vaccines?

Ab Osterhaus1, Ron Fouchier, Guus Rimmelzwaan

  • 1Department of Virology, Erasmus MC, Rotterdam, The Netherlands. a.osterhaus@erasmusmc.nl

Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|September 7, 2011
PubMed
Summary

Seasonal influenza vaccines are crucial for public health but require improvement, especially for vulnerable groups. Future vaccines aim for broader, longer protection and faster production using advanced technologies.

More Related Videos

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

Related Experiment Videos

Last Updated: May 29, 2026

Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays
13:12

Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays

Published on: April 4, 2011

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Seasonal influenza poses a significant disease burden, with current vaccines showing limitations in the elderly and immunocompromised.
  • Developing pandemic influenza vaccines faces challenges in production speed, capacity, efficacy, and safety.

Purpose of the Study:

  • To review current limitations in influenza vaccine technology and production.
  • To explore emerging strategies for enhancing influenza vaccine efficacy, safety, and production efficiency.
  • To discuss the potential for developing more universal influenza vaccines.

Main Methods:

  • Review of advancements in vaccine production technologies, including cell culture and reverse genetics.
  • Exploration of novel vaccine targets beyond hemagglutinin, such as neuraminidase and M2 proteins.
  • Investigation of the role of cell-mediated immunity, new adjuvants, and viral vector systems.

Main Results:

  • Cell culture and reverse genetics offer faster and potentially more scalable vaccine production.
  • Identifying new targets and enhancing immune responses through adjuvants and viral vectors can broaden protection.
  • Improved understanding of immune correlates may lead to more effective vaccine design.

Conclusions:

  • Technological advancements promise more efficient production of influenza vaccines.
  • Exploiting new targets and immune-modulating strategies can lead to broader, longer-lasting protection.
  • The development of universal influenza vaccines is a key future goal for improved global health security.